CARDIFF ONCOLOGY, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $27.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $11.53M, a 16.42% decline year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $15.83M, a 25.45% decline year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $16.57M, a 267.37% increase year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $19.52M, a 93.45% increase year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $71.11M, a 162.34% increase from fiscal 2024.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $27.11M, a 68.68% decline from fiscal 2023.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $86.55M, a 13.22% increase from fiscal 2022.
- CARDIFF ONCOLOGY, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $76.44M, a 169.26% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $27.35M 10-Q · filed 2026-08-11 | $43.93M derived: sum of 3 quarters · filed 2026-08-11 | $63.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $15.83M 10-Q · filed 2026-05-14 | $32.40M derived: sum of 2 quarters · filed 2026-05-14 | $51.92M derived: sum of 3 quarters · filed 2026-05-14 | $65.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $36.09M derived: sum of 2 quarters · filed 2026-02-24 | $49.88M derived: sum of 3 quarters · filed 2026-08-11 | $71.11M 10-K · filed 2026-02-24 |
| 2025-09-30 | $19.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $33.31M derived: sum of 2 quarters · filed 2026-08-11 | $54.54M 10-Q · filed 2025-11-06 | $59.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $13.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $35.02M 10-Q · filed 2026-08-11 | $39.53M derived: sum of 3 quarters · filed 2026-08-11 | $49.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $21.23M 10-Q · filed 2026-05-14 | $25.74M derived: sum of 2 quarters · filed 2026-05-14 | $35.83M derived: sum of 3 quarters · filed 2026-05-14 | $42.70M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $14.60M derived: sum of 2 quarters · filed 2026-02-24 | $21.47M derived: sum of 3 quarters · filed 2026-02-24 | $27.11M 10-K · filed 2026-02-24 |
| 2024-09-30 | $10.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $16.96M derived: sum of 2 quarters · filed 2025-11-06 | $22.59M 10-Q · filed 2025-11-06 | $28.61M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $12.51M 10-Q · filed 2025-07-29 | $18.52M derived: sum of 3 quarters · filed 2025-07-29 | $30.79M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $5.63M 10-Q · filed 2025-05-08 | $11.65M derived: sum of 2 quarters · filed 2025-05-08 | $23.92M derived: sum of 3 quarters · filed 2025-05-08 | $49.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $18.29M derived: sum of 2 quarters · filed 2025-02-27 | $43.57M derived: sum of 3 quarters · filed 2025-02-27 | $86.55M 10-K · filed 2025-02-27 |
| 2023-09-30 | $12.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $37.55M derived: sum of 2 quarters · filed 2024-11-07 | $80.53M 10-Q · filed 2024-11-07 | $95.75M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $25.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $68.27M 10-Q · filed 2024-08-08 | $83.48M derived: sum of 3 quarters · filed 2024-08-08 | $95.91M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $42.98M 10-Q · filed 2024-05-02 | $58.20M derived: sum of 2 quarters · filed 2024-05-02 | $70.63M derived: sum of 3 quarters · filed 2024-05-02 | $81.21M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $15.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $27.64M derived: sum of 2 quarters · filed 2024-02-29 | $38.23M derived: sum of 3 quarters · filed 2024-02-29 | $76.44M 10-K · filed 2024-02-29 |
| 2022-09-30 | $12.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $23.01M derived: sum of 2 quarters · filed 2023-11-02 | $61.23M 10-Q · filed 2023-11-02 | $74.52M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $10.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $48.80M 10-Q · filed 2023-08-09 | $62.09M derived: sum of 3 quarters · filed 2023-08-09 | $71.68M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $38.22M 10-Q · filed 2023-05-04 | $51.51M derived: sum of 2 quarters · filed 2023-05-04 | $61.10M derived: sum of 3 quarters · filed 2023-05-04 | $66.61M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $22.88M derived: sum of 2 quarters · filed 2023-03-02 | $28.39M derived: sum of 3 quarters · filed 2023-03-02 | $28.39M 10-K · filed 2023-03-02 |
| 2021-09-30 | $9.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $15.10M derived: sum of 2 quarters · filed 2022-11-03 | $15.10M 10-Q · filed 2022-11-03 | $15.10M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $5.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.51M 10-Q · filed 2022-08-04 | $5.51M derived: sum of 3 quarters · filed 2022-08-04 | $5.51M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |